1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

Opaleye Management Inc. Buys Aptose Biosciences Inc, Ocular Therapeutix Inc, Intra-Cellular Therapies Inc, Sells Cara Therapeutics Inc, ShockWave Medical Inc, NextCure Inc

Cambridge, MA, based Investment company Opaleye Management Inc. (Current Portfolio) buys Aptose Biosciences Inc, Ocular Therapeutix Inc, Intra-Cellular Therapies Inc, Edap TMS SA, Flexion Therapeutics Inc, sells Cara Therapeutics Inc, ShockWave Medical Inc, NextCure Inc, Strongbridge Biopharma PLC, Quanterix Corp during the 3-months ended 2019Q4, according to the most recent filings of the investment company, Opaleye Management Inc.. As of 2019Q4, Opaleye Management Inc. owns 44 stocks with a total value of $487 million. These are the details of the buys and sells.

For the details of Opaleye Management Inc.'s stock buys and sells, go to https://www.gurufocus.com/guru/opaleye+management+inc./current-portfolio/portfolio

These are the top 5 holdings of Opaleye Management Inc.
  1. Epizyme Inc (EPZM) - 1,384,200 shares, 6.99% of the total portfolio. Shares added by 1.41%
  2. Aptose Biosciences Inc (APTO) - 4,085,000 shares, 4.76% of the total portfolio. Shares added by 467.36%
  3. Codexis Inc (CDXS) - 1,400,000 shares, 4.58% of the total portfolio. Shares added by 3.70%
  4. Forty Seven Inc (FTSV) - 562,000 shares, 4.54% of the total portfolio. Shares added by 32.24%
  5. Stereotaxis Inc (STXS) - 4,112,500 shares, 4.52% of the total portfolio. Shares added by 1.04%
New Purchase: Achillion Pharmaceuticals Inc (ACHN)

Opaleye Management Inc. initiated holding in Achillion Pharmaceuticals Inc. The purchase prices were between $3.55 and $6.45, with an estimated average price of $5.83. The stock is now traded at around $6.76. The impact to a portfolio due to this purchase was 0.94%. The holding were 760,000 shares as of .

New Purchase: Aquestive Therapeutics Inc (AQST)

Opaleye Management Inc. initiated holding in Aquestive Therapeutics Inc. The purchase prices were between $3.06 and $8.78, with an estimated average price of $5.27. The stock is now traded at around $4.38. The impact to a portfolio due to this purchase was 0.88%. The holding were 738,500 shares as of .

New Purchase: Kadmon Holdings Inc (KDMN)

Opaleye Management Inc. initiated holding in Kadmon Holdings Inc. The purchase prices were between $2.58 and $4.98, with an estimated average price of $3.71. The stock is now traded at around $4.52. The impact to a portfolio due to this purchase was 0.87%. The holding were 940,373 shares as of .

New Purchase: Rhythm Pharmaceuticals Inc (RYTM)

Opaleye Management Inc. initiated holding in Rhythm Pharmaceuticals Inc. The purchase prices were between $19.53 and $25.5, with an estimated average price of $22.27. The stock is now traded at around $17.87. The impact to a portfolio due to this purchase was 0.52%. The holding were 110,500 shares as of .

New Purchase: Macrogenics Inc (MGNX)

Opaleye Management Inc. initiated holding in Macrogenics Inc. The purchase prices were between $7.95 and $12.27, with an estimated average price of $9.88. The stock is now traded at around $10.16. The impact to a portfolio due to this purchase was 0.45%. The holding were 200,500 shares as of .

New Purchase: Fennec Pharmaceuticals Inc (FENC)

Opaleye Management Inc. initiated holding in Fennec Pharmaceuticals Inc. The purchase prices were between $4.25 and $6.49, with an estimated average price of $5.39. The stock is now traded at around $7.82. The impact to a portfolio due to this purchase was 0.02%. The holding were 12,000 shares as of .

Added: Aptose Biosciences Inc (APTO)

Opaleye Management Inc. added to a holding in Aptose Biosciences Inc by 467.36%. The purchase prices were between $1.83 and $5.67, with an estimated average price of $2.95. The stock is now traded at around $8.26. The impact to a portfolio due to this purchase was 3.92%. The holding were 4,085,000 shares as of .

Added: Ocular Therapeutix Inc (OCUL)

Opaleye Management Inc. added to a holding in Ocular Therapeutix Inc by 84.05%. The purchase prices were between $2.57 and $4.73, with an estimated average price of $3.51. The stock is now traded at around $5.19. The impact to a portfolio due to this purchase was 1.89%. The holding were 5,107,500 shares as of .

Added: Intra-Cellular Therapies Inc (ITCI)

Opaleye Management Inc. added to a holding in Intra-Cellular Therapies Inc by 139.18%. The purchase prices were between $7.76 and $38.49, with an estimated average price of $12.45. The stock is now traded at around $22.84. The impact to a portfolio due to this purchase was 1.66%. The holding were 406,600 shares as of .

Added: Edap TMS SA (EDAP)

Opaleye Management Inc. added to a holding in Edap TMS SA by 495.00%. The purchase prices were between $4.3 and $5.38, with an estimated average price of $4.7. The stock is now traded at around $3.77. The impact to a portfolio due to this purchase was 1.35%. The holding were 1,785,000 shares as of .

Added: Flexion Therapeutics Inc (FLXN)

Opaleye Management Inc. added to a holding in Flexion Therapeutics Inc by 295.71%. The purchase prices were between $12.88 and $20.95, with an estimated average price of $16.97. The stock is now traded at around $16.53. The impact to a portfolio due to this purchase was 1.32%. The holding were 415,500 shares as of .

Added: ChemoCentryx Inc (CCXI)

Opaleye Management Inc. added to a holding in ChemoCentryx Inc by 80.80%. The purchase prices were between $6.89 and $39.55, with an estimated average price of $18.21. The stock is now traded at around $48.00. The impact to a portfolio due to this purchase was 1.27%. The holding were 361,600 shares as of .

Sold Out: Cara Therapeutics Inc (CARA)

Opaleye Management Inc. sold out a holding in Cara Therapeutics Inc. The sale prices were between $16.11 and $25.98, with an estimated average price of $19.58.

Sold Out: ShockWave Medical Inc (SWAV)

Opaleye Management Inc. sold out a holding in ShockWave Medical Inc. The sale prices were between $29.4 and $44.98, with an estimated average price of $37.19.

Sold Out: NextCure Inc (NXTC)

Opaleye Management Inc. sold out a holding in NextCure Inc. The sale prices were between $25 and $92.22, with an estimated average price of $42.28.

Sold Out: Strongbridge Biopharma PLC (SBBP)

Opaleye Management Inc. sold out a holding in Strongbridge Biopharma PLC. The sale prices were between $1.47 and $2.42, with an estimated average price of $1.91.

Sold Out: CymaBay Therapeutics Inc (CBAY)

Opaleye Management Inc. sold out a holding in CymaBay Therapeutics Inc. The sale prices were between $1.33 and $5.93, with an estimated average price of $3.68.

Sold Out: Vermillion Inc (VRML)

Opaleye Management Inc. sold out a holding in Vermillion Inc. The sale prices were between $0.38 and $0.95, with an estimated average price of $0.67.



Here is the complete portfolio of Opaleye Management Inc.. Also check out:

1. Opaleye Management Inc.'s Undervalued Stocks
2. Opaleye Management Inc.'s Top Growth Companies, and
3. Opaleye Management Inc.'s High Yield stocks
4. Stocks that Opaleye Management Inc. keeps buying

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:



Performances of the stocks mentioned by insider


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)